Demyelination is the loss or destruction of myelin, the insulating sheath surrounding many nerve fibers in the nervous system. It impairs the speed and reliability of electrical signaling and can eventually contribute to damage of the underlying axons. Demyelination is a pathological process rather than a single disease: it occurs in several inflammatory, infectious, metabolic, toxic, and inherited disorders. Its effects depend on the location, extent, and cause of myelin damage.
Biological basis
Myelin consists of tightly wrapped layers of specialized cell membrane. In the central nervous system—the brain and spinal cord—it is produced by oligodendrocytes. In the peripheral nervous system, it is produced by Schwann cells. One oligodendrocyte can myelinate portions of multiple axons, whereas a myelinating Schwann cell normally forms one segment of myelin around a single axon.
Myelin enables saltatory conduction: electrical impulses are regenerated at gaps between myelin segments, called nodes of Ranvier, rather than continuously along the entire axon. Myelin loss increases electrical current leakage and changes the electrical properties of the nerve fiber. Impulses may slow, become poorly synchronized, or fail to propagate, producing conduction block.
Demyelinated axons can partly compensate by redistributing ion channels along their exposed membranes. However, maintaining conduction becomes more energetically demanding. Persistent demyelination, inflammation, and loss of support from myelin-forming cells can contribute to irreversible axonal injury.
Pathological distinctions
Primary demyelination refers to damage directed principally at myelin or its supporting cells, with relative preservation of axons early in the process. This differs from secondary myelin breakdown following primary axonal degeneration. The distinction is useful in pathology, although both processes may coexist in advanced disease.
Demyelination also differs from hypomyelination, in which insufficient myelin is formed during development. Dysmyelination generally describes abnormal myelin formation or maintenance, particularly in inherited disorders. These terms are not interchangeable, although some diseases involve both abnormal myelin production and subsequent myelin loss.
Although myelin is a major component of white matter, demyelination is not restricted to it. Myelinated fibers also occur in gray matter, including the cerebral cortex, where demyelinating lesions can develop.
Causes and associated disorders
Central nervous system
Multiple sclerosis is a major acquired inflammatory demyelinating disease of the central nervous system. Its lesions can involve the brain, optic nerves, and spinal cord. Myelin loss occurs alongside varying degrees of axonal injury and inflammatory activity.
Other central nervous system conditions include:
- Acute disseminated encephalomyelitis: an inflammatory disorder characterized by multifocal neurological abnormalities and encephalopathy, occurring predominantly in children and often following an infection.
- Myelin oligodendrocyte glycoprotein antibody-associated disease: a distinct inflammatory disorder that can produce optic neuritis, spinal cord inflammation, or brain inflammation.
- Progressive multifocal leukoencephalopathy: an opportunistic infection caused by JC virus, which damages oligodendrocytes and produces demyelination, usually in people with impaired immune function.
- Osmotic demyelination syndrome: a disorder associated with major disturbances in osmotic balance, classically following overly rapid correction of chronic hyponatremia.
- Metabolic and toxic disorders: severe vitamin B12 deficiency and certain toxic exposures can damage myelin, sometimes together with axons.
Not every disorder traditionally grouped with demyelinating diseases begins with a primary attack on myelin. For example, aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder primarily targets astrocytes, with myelin damage occurring as part of the resulting tissue injury.
Peripheral nervous system
Peripheral demyelination occurs in acquired and inherited neuropathies. Acute inflammatory demyelinating polyradiculoneuropathy is a major subtype of Guillain–Barré syndrome, although other Guillain–Barré subtypes primarily affect axons.
Chronic inflammatory demyelinating polyneuropathy is an immune-mediated disorder with a chronic or relapsing course. Some inherited neuropathies, including certain forms of Charcot–Marie–Tooth disease, also involve abnormal peripheral myelin.
Clinical manifestations
Symptoms reflect which pathways are affected rather than demyelination alone.
Central nervous system lesions may cause reduced vision, weakness, altered sensation, impaired coordination, abnormal eye movements, or bladder dysfunction. Some disorders also affect cognition. Peripheral demyelination commonly produces weakness, sensory disturbances, and reduced or absent tendon reflexes.
In some demyelinating disorders, increased body temperature temporarily worsens neurological symptoms because conduction through previously damaged fibers becomes less reliable. Such worsening does not necessarily indicate new myelin injury.
Clinical courses vary substantially. An episode may be followed by substantial recovery, recurrent attacks, persistent deficits, or progressive disability.
Investigation and interpretation
Evaluation combines the clinical pattern, neurological examination, and investigations selected for the suspected disorder.
Magnetic resonance imaging is central to assessing suspected central nervous system demyelination. Lesion location, distribution, and evolution can help distinguish causes. However, an abnormal white-matter signal is not proof of demyelination: vascular injury, infection, and other processes can produce similar appearances.
Analysis of cerebrospinal fluid may reveal inflammation or evidence of antibody production within the central nervous system. These findings require interpretation in context and are not universally present or specific to one disease.
For peripheral disorders, nerve conduction studies can identify patterns consistent with demyelination, including marked conduction slowing, prolonged latencies, temporal dispersion, and conduction block. Blood tests may investigate metabolic, infectious, immune-mediated, or inherited causes.
Tissue biopsy is reserved for selected circumstances rather than routinely used to establish demyelination.
Repair and treatment principles
Remyelination is the formation of new myelin around demyelinated axons. It can restore more effective conduction and support axonal survival, but its extent varies. Recovery can also result from resolution of inflammation and physiological adaptation without complete myelin repair.
Treatment is directed at the underlying disorder, not at demyelination as a single entity. Depending on the diagnosis, established approaches include immune-modifying treatment, management of an infection or metabolic disturbance, and correction of a nutritional deficiency. Rehabilitation addresses functional consequences.
Treatments that suppress new inflammatory injury do not necessarily repair existing myelin or replace lost axons. Promoting durable remyelination and preventing axonal degeneration remain important areas of research.